September 5, 2013 – RSA, a global life sciences executive search and interim management specialist, has appointed Chris Molloy as its new chief executive officer. Mr. Molloy brings to RSA over 20 years' experience of international life sciences across the pharmaceutical, biotechnology and start-up sectors. He began his career with Glaxo, where he held a range of management, research, business change and scientific collaboration roles. Moving to Asia in 2004 he became COO of the emerging biotech firm MerLion Pharmaceuticals, where he was also responsible for fundraising and business development. Most recently he has been VP corporate development and marketing at IDBS. Mr. Molloy has also been a non-executive member of the RSA board since 2009. “The time has come to prepare for the next step in our evolution. We are excited to have Chris on board as RSA's CEO. He will continue to preserve the special culture and feel of RSA whilst making ourselves even more professional as an executive search and interim business,” said Nick Stephens, executive chairman of RSA.
Share This Article